Pharvaris N.V.

NasdaqGS PHVS

Pharvaris N.V. Price to Earnings Ratio (P/E) on December 30, 2024: -7.17

Pharvaris N.V. Price to Earnings Ratio (P/E) is -7.17 on December 30, 2024, a 58.33% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Pharvaris N.V. 52-week high Price to Earnings Ratio (P/E) is -6.63 on October 10, 2024, which is 7.56% above the current Price to Earnings Ratio (P/E).
Pharvaris N.V. 52-week low Price to Earnings Ratio (P/E) is -19.81 on February 05, 2024, which is -176.33% below the current Price to Earnings Ratio (P/E).
Pharvaris N.V. average Price to Earnings Ratio (P/E) for the last 52 weeks is -10.77.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: PHVS

Pharvaris N.V.

CEO	Mr. Berndt Axel Edvard Modig CPA, M.B.A.
IPO Date	Feb. 5, 2021
Location	Netherlands
Headquarters	J.H. Oortweg 21
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Key trends

Past 5 years